DOI QR코드

DOI QR Code

Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia

  • Rattanaburi, Athithan (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Prince of Songkla University) ;
  • Boonyapipat, Sathana (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Prince of Songkla University) ;
  • Supasinth, Yuthasak (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Prince of Songkla University)
  • Published : 2015.07.13

Abstract

Background: An hCG regression curve has been used to predict the natural history and response to chemotherapy in gestational trophoblastic disease. We constructed hCG regression curves in high-risk gestational trophoblastic neoplasia (GTN) treated with EMA/CO and identified an optimal hCG level to detect EMA/CO resistance in GTN. Materials and Methods: Eighty-one women with GTN treated with EMA/CO were classified as primary high-risk GTN (n = 65) and single agent-resistance GTN (n = 16). The hCG levels prior to each course of chemotherapy were plotted in the 10th, 50th, and 90th percentiles to construct the hCG regression curves. Diagnostic performance was evaluated for an optimal cut-off value. Results: The median hCG levels were 264,482 mIU/mL mIU/mL and 495.5 mIU/mL mIU/mL for primary high-risk GTN and single agent-resistance GTN, respectively. The 50th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 4th and the 2nd course of chemotherapy, respectively. The 90th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 9th and the 2nd course of chemotherapy, respectively. The hCG level of ${\geq}118.6mIU/mL$ mIU/mL at the 5thcourse of EMA/CO predicted the EMA/CO resistance in primary high-risk GTN patients with a sensitivity of 85.7% and a specificity of 100%. Conclusion: EMA/CO resistance in primary high-risk GTN can be predicted by using an hCG regression curve in combination with the cut-off value of 118.6 mIU/mL at the 5thcourse of chemotherapy.

Keywords

EMA/CO;gestational trophoblastic neoplasia;human chorionic gonadotropin;drug resistance

References

  1. Bianconi M, Jankilevich G, Otero S, Nassif J, Storino C(2007).Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol, 106, 268-71. https://doi.org/10.1016/j.ygyno.2007.04.002
  2. Bolis G, BonazziC, Landoni F, et al (1988). EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol, 31, 439-44. https://doi.org/10.1016/S0090-8258(88)80029-5
  3. Bower M, Newlands ES, Holden L, et al (1997). EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol, 15, 2636-43. https://doi.org/10.1200/JCO.1997.15.7.2636
  4. Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA (2003). Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol, 91, 552-7. https://doi.org/10.1016/j.ygyno.2003.08.028
  5. Lurain JR (2011). Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol, 204, 11-8. https://doi.org/10.1016/j.ajog.2010.06.072
  6. LybolC, Westerdijk K, Sweep FC, et al (2012). Human chorionic gonadotropin (hCG) regression nomograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. Ann Oncol, 23, 2903-06. https://doi.org/10.1093/annonc/mds199
  7. Manopunya M, Suprasert P (2012). Resistant gestational trophoblastic neoplasia patients treated with 5-fluouracil plus actinomycin D. Asian Pac J Cancer Prev, 13, 387-90. https://doi.org/10.7314/APJCP.2012.13.1.387
  8. Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L(1991). Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol, 98, 550-7. https://doi.org/10.1111/j.1471-0528.1991.tb10369.x
  9. Ngan HY, Bender H, Benedet JL, et al (2003). Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet, 83, 175-7. https://doi.org/10.1016/S0020-7292(03)90120-2
  10. Ngan HYS, Kohorn EI, Cole LA, et al (2012). Trophoblastic disease. Int J Gynecol Obstet, 119, 130-6. https://doi.org/10.1016/j.ijgo.2012.05.019
  11. Oranratanaphan S, Lertkhachonsuk R (2014). Treatment of extremely high risk and resistant gestational trophoblastic neoplasia patients in king chulalongkorn memorial hospital. Asian Pac J Cancer Prev, 15, 925-8. https://doi.org/10.7314/APJCP.2014.15.2.925
  12. Pongsaranantakul S, Kietpeerakool C (2009). Hysterectomy in gestational trophoblastic neoplasia: Chiang Mai University Hospital's experience. Asian Pac J Cancer Prev, 10, 311-4.
  13. Powles T, Savage PM, Stebbing J, et al (2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer, 96, 732-7. https://doi.org/10.1038/sj.bjc.6603608
  14. Shigematsu T, Kamura T, Saito T, et al (1998). Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol Oncol, 71, 376-80. https://doi.org/10.1006/gyno.1998.5210
  15. van Trommel NE, Massuger LF, Schijf CP, et al (2006). Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol, 24, 52-8. https://doi.org/10.1200/JCO.2005.03.3043
  16. van Trommel NE, Ngo Duc H, Massuger LF, et al (2008). Early identification of persistent trophoblastic disease with serum hCG concentration ratios. Int J Gynecol Cancer, 18, 318-23. https://doi.org/10.1111/j.1525-1438.2007.00993.x
  17. WangJ, Short D, Sebire NJ, et al (2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol, 19, 1578-83. https://doi.org/10.1093/annonc/mdn181